Tissue Engineering And Nanotheranostics

b2815 Tissue Engineering and Nanotheranostics “9.61x6.69”

272 Tissue Engineering and Nanotheranostics

209. Zhang L, Lu Z, Zhao Q, Huang J, Shen H, Zhang Z. Enhanced
     chemotherapy efficacy by sequential delivery of siRNA and antican­
     cer drugs using PEI­grafted graphene oxide. Small 7 , 460–464
     (2011).


210. Choi HY, Lee TJ, Yang GM, Oh J, Won J, Han J, Jeong GJ, Kim J,
     Kim JH, Kim BS, Cho SG. Efficient mRNA delivery with graphene
     oxide­polyethylenimine for generation of footprint­free human induced
     pluripotent stem cells. J. Control. Rel. 235 , 222–235 (2016).


211. Dong H, Ding L, Yan F, Ji H, Ju H. The use of polyethylenimine­
     grafted graphene nanoribbon for cellular delivery of locked nucleic
     acid modified molecular beacon for recognition of microRNA.
     Biomaterials 32 , 3875–3882 (2011).


212. Hubert A, Lyass O, Pode D, Gabizon A. Doxil (Caelyx): An explora­
     tory study with pharmacokinetics in patients with hormone­refractory
     prostate cancer. Anti-cancer Drugs 11 , 123–127 (2000).


213. Orditura M, Quaglia F, Morgillo F, Martinelli E, Lieto E, De Rosa G,
     Comunale D, Diadema MR, Ciardiello F, Catalano G, De Vita F.
     Pegylated liposomal doxorubicin: pharmacologic and clinical evidence
     of potent antitumor activity with reduced anthracycline­induced car­
     diotoxicity (review). Oncol. Rep. 12 , 549–556 (2004).


214. Goto S, Ihara Y, Urata Y, Izumi S, Abe K, Koji T, Kondo T.
     Doxorubicin­induced DNA intercalation and scavenging by nuclear
     glutathione S­transferase pi. FASEB Journal 15 , 2702–2714 (2001).


215. Peer D, Park EJ, Morishita Y, Carman CV, Shimaoka M. Systemic
     leukocyte­directed siRNA delivery revealing cyclin D1 as an anti­
     inflammatory target. Science 319 , 627–630 (2008).


216. Schiffelers RM, Storm G. ICS­283: A system for targeted intravenous
     delivery of siRNA. Expert Opin. Drug Delivery 3 , 445–454 (2006).


217. Torchilin VP. Drug targeting. Eur. J. Phar. Sci. 11 (2), S81–S91
     (2000).


218. Lammers T, Kiessling F, Hennink WE, Storm G. Drug targeting to
     tumors: principles, pitfalls and (pre­) clinical progress. J. Control. Rel.
     161 , 175–187 (2012).


219. Lopez­Davila V, Seifalian AM, Loizidou M. Organic nanocarriers for
     cancer drug delivery. Curr. Opin. Pharm. 12 , 414–419 (2012).


220. Maeda H, Nakamura H, Fang J. The EPR effect for macromolecular
     drug delivery to solid tumors: Improvement of tumor uptake, lowering
     of systemic toxicity, and distinct tumor imaging in vivo. Adv. Drug
     Delivery Rev. 65 , 71–79 (2013).